A Safety Study of ARRY-300 in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Array BioPharma
ClinicalTrials.gov Identifier:
NCT00828165
First received: January 22, 2009
Last updated: August 29, 2012
Last verified: August 2012

January 22, 2009
August 29, 2012
January 2009
April 2009   (final data collection date for primary outcome measure)
  • Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms. [ Time Frame: Duration of study ] [ Designated as safety issue: Yes ]
  • Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations. [ Time Frame: Following a single dose ] [ Designated as safety issue: No ]
  • Adverse Events [ Time Frame: Screening - Follow-up ] [ Designated as safety issue: Yes ]
  • Plasma concentrations of ARRY-300 and a sulfoxide metabolite [ Time Frame: Following a single dose ] [ Designated as safety issue: No ]
  • Findings on physical examination and clinical laboratory abnormalities [ Time Frame: Day 1 - Follow-up ] [ Designated as safety issue: Yes ]
  • Change in vital sign measurements [ Time Frame: Day 1 - Follow-up ] [ Designated as safety issue: Yes ]
  • Change in 12-lead electrocardiogram (ECG) parameters [ Time Frame: Day 1 - Follow-up ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00828165 on ClinicalTrials.gov Archive Site
Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers. [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
Characterization of the pharmacodynamic (PD) activity of ARRY-300 on biomarkers in whole blood after a single oral dose. The percent of pre-initial-dose levels of these cytokines will be correlated with plasma concentrations. [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Safety Study of ARRY-300 in Healthy Subjects
Not Provided

This is a Phase 1 study, involving a 1-day dosing period (up to 3 dosing periods per subject), designed to test the safety of investigational study drug ARRY-300 in healthy subjects. Approximately 12 healthy subjects from the US will be enrolled in this study.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Healthy
  • Drug: ARRY-300, MEK inhibitor; oral
    single dose, escalating
  • Drug: Placebo
    matching placebo
  • Experimental: ARRY-300
    Intervention: Drug: ARRY-300, MEK inhibitor; oral
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
April 2009
April 2009   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Healthy male or female (females must be of non-childbearing potential) between the ages of 18 and 50 years, inclusive.
  • Body mass index (BMI) of 18 kg/m2 to 35 kg/m2; and a total body weight > 50 kg (110 lbs) and < 113 kg (280 lbs).
  • Additional criteria exist.

Key Exclusion Criteria:

  • Evidence or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, dermatologic, or allergic disease (including drug allergies that are clinically significant and not remote, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • A condition possibly affecting drug absorption (e.g., gastrectomy).
  • Women who are pregnant or breastfeeding.
  • A positive test for drugs or alcohol.
  • Use of tobacco- or nicotine-containing products in excess of 5 cigarettes per day, or daily use of pipe, cigar, chewing tobacco or nicotine gum or patches.
  • Treatment with an investigational drug within 30 days prior to first dose of study drug.
  • Use of prescription or nonprescription drugs, vitamins, grapefruit juice, and dietary or herbal supplements within 14 days prior to the first dose of study drug. As exceptions, acetaminophen may be used at doses of ≤ 1 g/day or ibuprofen may be used at doses of ≤ 800 mg/day until 24 hours prior to first dose of study drug.
  • Blood donation of ≥ 1 pint within 30 days prior to first dose of study drug.
  • Evidence of hepatitis B or C, or human immunodeficiency virus (HIV) infection upon serological testing.
  • Additional criteria exist.
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00828165
ARRAY-300-101
No
Array BioPharma
Array BioPharma
Not Provided
Not Provided
Array BioPharma
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP